Drugs / Insulin glargine/Lixisenatide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05114590 | Jan 2022 → Mar 2023 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin glargine/Lixisenatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05114590 ↗ |
| Route | Subcutaneous | “Solution for injection in a pre-filled pen by subcutaneous injection.” NCT05114590 ↗ |